ClinicalTrials.gg
RecruitingNCT07501377INFLAMEUpdated Mar 30, 2026

Effects of a 6-months Fiber- and Polyphenol-rich Diet on Brain Inflammatory Processes in Perimenopausal Women Living With Overweight or Obesity

An interventional study of Polybiotic dietary intervention and Placebo in Overweight and/or Obesity and Perimenopausal Women, sponsored by Max Planck Institute for Human Cognitive and Brain Sciences. Recruiting at 1 site in Germany. Open to female participants aged 35 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-30.

Primary conditionObesityRegistry: Neuroinflammatory DiseasesReclassifiedWhy we changed it
Registry
Neuroinflammatory Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. Neuroinflammatory Diseases is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Obesity.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Max Planck Institute for Human Cognitive and Brain Sciences · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
35 Years to 60 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 338 studies in Obesity with a site in Germany — 75 open to participants now, 110 under way, 49 of them phase 3. Obesity · Germany.

Planned enrollment
154th of 276
120 · median 160
Started
2026
with 48 others
No phase
106 of 338
18 open now
Primary completion
2029-06
later than 94 of 109 live
Registered
301st of 338
by date

Among the 338 studies in Obesity with a site in Germany, this one is the 154th largest by planned enrollment of the 276 interventional ones that give a count, is one of 49 that started in 2026, is one of 106 with no phase, reaches primary completion later than 94 of the 109 other live ones, and was the 301st registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

75 of the 338 studies in Obesity with a site in Germany are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 35 Years to 60 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 338 studies in Obesity with a site in Germany, or all of them as a file.
02

Study summary

People living with obesity have a higher risk of late-life cognitive decline and developing dementia. In women, the risk of cognitive decline may further raise during the menopausal transition, a period of substantial hormonal and metabolic changes.

Recent studies suggest that a healthy diet could help to prevent neurocognitive disorders by reducing inflammatory processes in the body and brain. Emerging evidence further indicates that the gut-brain axis and the intestinal microbiome play a crucial role in mediating this effect, through metabolic, immune, neuronal and vascular routes. Modifying the gut microbiota may thus counteract the heightened systemic inflammation seen in obesity and during menopausal transition to eventually benefit brain health.

Specifically, plant-based nutirents, such as fibre and polyphenols, have microbiome-changing, anti-inflammatory and neuroprotective properties that may slow brain aging and neuro-inflammation. However, evidence from human interventional studies and knowledge on the underlying mechanisms remain scarce.

This randomized controlled trial will therefore test whether altering gut bacteria through six months of daily intake of a personalized "polybiotic" dietary formula, compared to placebo, improves markers of brain health in women during the perimenopausal transition that are living with overweight or obesity. We plan to enroll 120 women aged 35-60 with overweight/obesity and elevated inflammatory blood markers, randomized to: intervention (7.5 or 15 g inulin, plus 200 mg resveratrol and 320 mg quercetin per day in powder form with main meals) or control (isocaloric maltodextrin). Exclusions include type 1 diabetes, current psychiatric/gastrointestinal disorders, and magentic resonance imaging (MRI) contraindications.

Before and after 26 weeks, participants will undergo brain MRI to assess inflammation-related brain markers, neuropsychological testing, anthropometric measurements, they will fill in a set of questionnaires and donate stool and blood. Gut bacteria will be profiled by next-generation sequencing; metabolites will be measured in blood and stool. The primary outcome is a proxy of neuroinflammation in the white matter assessed using diffusion-weighted MRI. Secondary analyses will examine blood-brain-barrier permeability and other functional and structural MRI measures, including MR spectoscropy. Mechanistic links among changes in inflammatory markers, microbiota composition, and short-chain fatty acids will be explored using path and network models.

This study may help to develop novel prevention and treatment strategies to mitigate obesity-related cognitive decline via the gut-brain axis.

03

Conditions studied

  • Overweight and/or Obesity
  • Perimenopausal Women

Browse trials for

Keywords

  • neuroinflammation
  • obesity
  • overweight
  • menopausal transition
  • gut-brain axis
  • diet
  • diffusion-weighted MRI
  • cognitive decline
  • brain aging
  • MR spectroscopy
  • prevention
  • open science
04

In context

Obesity Reclassified

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's planned enrollment of 120 is above the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Max Planck Institute for Human Cognitive and Brain Sciences is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neuroinflammatory Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
35 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • STRAW+10 -1 or -2
  • > 25 or WHR >= 0.85
  • hsCRP > 1 mg/l
  • no MRI
  • written

Exclusion criteria

Exclusion Criteria:

  • occurrence of a psychiatric disease in the last 12 months (e.g., depression, substance abuse, eating disorder, schizophrenia)
  • type 1 diabetes
  • previous bariatric/gastric surgery
  • pregnancy or breastfeeding woman
  • severe untreated disease, cancer treatment last 12 months, any chronic gastric tract disease (IBS, Morbus Crohn, Heliobacter pylori Infection etc.) or any chronic inflammatory disease
  • Polycystic ovary syndrome, total ovarectomy
  • Intake of antibiotics in past 3 months, intake of inulin (>5g/day) or polyphenol supplementation (>50mg/day) in past 3 months
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Personalized intervention arm

    Daily intake of 7.5g or 15g of inulin + 200mg resveratrol + 320mg quercetin in a powder formula with main meals in the first half of day, over the course of 6 months. The lower or higher inulin dosage will be assigned depending on the participants' microbiome composition at baseline.

    Dietary Supplement: Polybiotic dietary intervention

  • Placebo comparator
    Placebo arm

    Daily intake of equicaloric maltodextrin

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementPolybiotic dietary intervention

    7.5g or 15g of inulin + 200mg resveratrol + 320mg quercetin in a powder formula

  • Dietary supplementPlacebo

    Equicaloric maltodextrin in powder form

07

What researchers measure

Primary outcomes

  1. Free water fraction averaged across the white matter skeleton

    Free water (measured using multi-shell diffusion-weighted MRI at 3 Tesla) reflects extra-cellular water which can be considered an indicator of tissue edema and impaired blood brain barrier

    Time frame: 6 months

Secondary outcomes

  1. Average grey matter kw from motion-compensated diffusion-weighted arterial spin labeling (ASL)

    Water exchange rate over the blood-brain barrier will be measured using motion-compensated diffusion-weighted pseudo-continuous arterial-spin labeling (MCDW-ASL) or diffusion-prepared pCASL (DP-pCASL).

    Time frame: 6 months

  2. Apparent diffusion coefficient of metabolites in the thalamus from diffusion-weighted MR spectoscropy

    microglial activity will be quantified by measuring ADCCholine using diffusion-weighted magnetic resonance spectroscopy (dwMRS)

    Time frame: 6 months

  3. Hypothalamic and hippocampal microstructure

    microstructure will be assessed by mean diffusivity (MD)

    Time frame: 6 months

  4. Episodic memory

    California Verbal Learning Task

    Time frame: 6 months

  5. Microbial Composition

    Alpha/Beta diversity and abundance of specific bacteria (e.g. bifidobacteria) from microbiome shotgun sequencing

    Time frame: 6 months

Other outcomes

  1. soma signal fraction in thalamus and hippocampus derived from multi-shell diffusion-weighted MRI

    assessed using multi-shell diffusion-weighted MRI at 3T

    Time frame: 6 months

  2. Pattern separation

    Dprime and accuracy, reaction time of Mnemonic Similarity Task (MST)

    Time frame: 6 months

  3. Executive function

    Composite score of executive function tests derived from Trail Making Test, Attention Network Test, Stroop-Test

    Time frame: 6 months

  4. pro-inflammatory marker high-sensitive C-reactive protein (hsCRP)

    hsCRP measured in fasting blood

    Time frame: 6 months

  5. waist-to-hip ratio, WHR

    ratio of waist circumeference to hip circumference (measured)

    Time frame: 6 months

  6. Adherence to healthy dietary pattern

    A composite score based on self-reported information provided through diet protocol and food frequency questionnaire (FFQ)

    Time frame: 6 months

  7. Menopausal symptoms

    severity of menopausal symptoms based on a questionnaire

    Time frame: 6 months

  8. Assessment of health data

    via wearables - smart devices finger ring and/or watch and glucose patch

    Time frame: 6 months (during 2 weeks at baseline, and follow-up, respectively)

  9. Demographics, anamnesis

    Age, sex/gender, medical history, reproductive history, medication

    Time frame: 6 months

  10. Total energy expenditure measured using a metabolic chamber

    Oxygen consumption and CO2 production measured in a metabolic chamber, determining 24-hour total energy expenditure (TEE)

    Time frame: 6 months

  11. body fat percentage

    measured using bioelectrical impedance analysis (BIA)

    Time frame: 6 months

  12. Gastrointestinal hormones

    area under the curve (pre- to postprandial) of glukagon-like peptide 1 (GLP-1)

    Time frame: 6 months

  13. Sex hormones

    Follicle-stimulating hormon (FSH) measured in blood

    Time frame: 6 months

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jun 2029, 39 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 39 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2026
First posted
Mar 30, 2026
StartActual
Mar 19, 2026
Primary completionEst.
Jun 30, 2029
CompletionEst.
Dec 31, 2030
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07501377
Lead sponsor
Max Planck Institute for Human Cognitive and Brain Sciences
Responsible party
Sponsor
First posted
Mar 30, 2026
Start date
Mar 19, 2026
Primary completion
Jun 30, 2029 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Mar 30, 2026

Study contacts

Veronica Witte, PhD
principal investigator · University of Leipzig Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion